[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 5,083
Citations 0
Editorial
September 18, 2013

Renin-Angiotensin System Inhibition and Secondary Cardiovascular Prevention

Author Affiliations
  • 1Montreal Heart Institute, Montreal, Quebec, Canada
  • 2Department of Medicine, Université de Montréal, Montreal, Quebec, Canada
JAMA. 2013;310(11):1130-1131. doi:10.1001/jama.2013.277170

Cardiovascular diseases remain the leading cause of mortality in the world as recently confirmed by the World Health Organization, and atherosclerosis is the main underlying origin. Atherosclerosis-related diseases are also responsible for considerable morbidity in the United States and around the world1 and for health care costs related to hospitalizations for myocardial infarction, heart failure, and stroke. Although nonpharmacological strategies including a heart-healthy diet, physical activity, and smoking cessation should always be recommended, most patients with or at high risk of coronary artery disease should receive several medications including a statin, at least 1 antiplatelet agent, and a renin-angiotensin system inhibitor (angiotensin-converting enzyme [ACE] inhibitor or, if not well tolerated, an angiotensin receptor antagonist).2

First Page Preview View Large
First page PDF preview
First page PDF preview
×